Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

48 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-04-30

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Liver is an organ that is well-known for its immune tolerant capacity. However, there were still controversial issues about the impact of immunologic challenge after liver transplantation on the graft function. Different results of graft function affected by immunologic factors such as pre-transplant panel reactive antibody (PRA) status, pre-transplant positive lymphocyte cross match (LCM), or post-transplant circulating donor specific antibody (DSA) has been reported according to individual institutes. There was no trial for presenting anti-donor lymphocyte antibody change after liver transplantation.

The investigators designed this study to analyze the correlation between pre- and post-transplant immune status (PRA, LCM), and graft survival / rejection episode. Also, the investigators will find aspects of anti-donor lymphocyte antibody change after liver transplantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Persistent Lymphopenia in Liver Transplantation and Its Molecular Insights for Hepatocellular Carcinoma

NCT06368349

Lymphopenia

COMPLETED

Uses of Immunosuppression Therapy in Patients With Liver Transplantation

NCT01834690

Evidence of Liver Transplantation

COMPLETED

Immune Function Following Liver Transplantation

NCT04302246

Liver Transplant; Complications

COMPLETED

Liver Transplantation and Reticuloendothelial Clearance Capacity

NCT00929032

Hepatic Insufficiency Liver Insufficiency

COMPLETED

Antibodies and Liver Retransplantation

NCT03815864

Liver Transplant Failure Antibody-mediated Rejection

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Design: Target study population is forty patients who will undergo liver transplantation for 1 year in YUHS. Pediatric and early mortality cases will be excluded. Blood sample will be collected at pre-transplant period, post-transplant 7, 14, 21 day, 3 month and 6 month.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplant Rejection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liver transplant recipients

Recipients who will undergo liver transplantation during study period

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Liver recipients who undergo liver transplantation between Mar, 2011 and Feb, 2012
* Patients who can be followed for more than 3 months after transplantation

Exclusion Criteria

* Age under 20 years
* Multi-organ transplantation
* Not agree with informed consent
* Patient who had plant to be transferred to other country or center

Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No